Brad Robling
Director/Board Member at Auron Therapeutics, Inc.
Profile
Brad Robling is currently a Director at Auron Therapeutics, Inc. He previously worked as a Director-Investor Relations at Eli Lilly & Co.
Brad Robling active positions
| Companies | Position | Start |
|---|---|---|
Auron Therapeutics, Inc.
 Auron Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Auron Therapeutics, Inc. operates as a biotechnology company. It aims to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells. The company was founded by Kate Yen, Matt Vander Heiden, Ross Levine, and Eytan Stein and is headquartered in Wellesley, MA. | Director/Board Member | - |
Former positions of Brad Robling
| Companies | Position | End |
|---|---|---|
| ELI LILLY AND COMPANY | Public Communications Contact | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| Private companies | 1 |
|---|---|
Auron Therapeutics, Inc.
Auron Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Auron Therapeutics, Inc. operates as a biotechnology company. It aims to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells. The company was founded by Kate Yen, Matt Vander Heiden, Ross Levine, and Eytan Stein and is headquartered in Wellesley, MA. | Commercial Services |
- Stock Market
- Insiders
- Brad Robling
